Jefferies had predicted that IOVA could see a 5%-15% move on Replime’s drug getting rejected. ・According to Chardan analyst Geulah Livshits, RP1’s rejection is a positive for Iovance's Amtagvi's ...
Hosted on MSN
Why Are IOVA Shares Rising Today?
Iovance Biotherapeutics Inc. (IOVA) shares jumped nearly 25% in early trading on Thursday after the company posted a smaller-than-expected loss in the third quarter and reported revenue growth on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results